Drug Profile
Deoxycholic acid - Kythera Biopharmaceuticals
Alternative Names: ATX-101-Kythera; Belkyra; Kybella; Sodium deoxycholate; Sodium desoxycholateLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Kythera Biopharmaceuticals
- Developer Bayer Dermatology; Kythera Biopharmaceuticals
- Class Choleretics; Cholic acids; Gallstone therapies; Small molecules
- Mechanism of Action Cell membrane modulators; Membrane lipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Subcutaneous fat disorders
- No development reported Lipoma
Most Recent Events
- 24 Sep 2021 Launched for Subcutaneous fat disorders in Sweden, United Kingdom, Spain, Denmark, New Zealand, Switzerland, Netherlands, Norway, Norway, Poland, Czech Republic, Hungary, Finland, Hong Kong, Australia, Brazil, Canada (SC) before September 2021
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 12 Dec 2018 Registered for Subcutaneous fat disorders in United Kingdom, Slovenia, Slovakia, Slovakia, Poland, Spain, Denmark, Switzerland, Finland, Netherlands, Czech Republic, Cyprus, Belgium (SC), Portugal (SC), Greece, Italy, Luxembourg, Malta, Ireland, Germany (SC), France (SC)